The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2003-10-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1365-2125.2003.01955.XPMID 14678342PMCID PMC1884417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.

  2011cited by this paper
• Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype.

  2003cited by this paper
• The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization.

  2001cited by this paper
• Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.

  2001cited by this paper
• Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.

  2000cited by this paper
• The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.

  2000cited by this paper
• The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma.

  2000cited by this paper
• Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.

  2000cited by this paper
• Asthma exacerbations during long term â agonist use : influence of â 2 adrenoceptor polymorphism

  2000cited by this paper
• Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics

  1999cited by this paper
• β2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting β2-agonist therapy

  1999cited by this paper
• Effects of genetic polymorphism on ex vivo and in vivo function of beta2-adrenoceptors in asthmatic patients.

  1999cited by this paper
• In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol.

  1999cited by this paper
• Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy.

  1999cited by this paper
• Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment.

  1998cited by this paper
• Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol.

  1998cited by this paper
• The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs.

  1998cited by this paper
• Effects of treatment with formoterol on bronchoprotection against methacholine.

  1998cited by this paper
• Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.

  1997cited by this paper
• Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics.

  1997cited by this paper
• Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients.

  1997cited by this paper
• Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.

  1995cited by this paper
• Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.

  1993cited by this paper
• Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response.

  1993cited by this paper
• A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor.

  1993cited by this paper

• The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update

  2023cites this paper
• Development of Inhaled GABAA Receptor Modulators to Improve Airway Function in Bronchoconstrictive Disorders.

  2022cites this paper
• Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents

  2021cites this paper
• Achieving the balance between evidence and simplicity

  2020cites this paper
• Bronchodilatateurs

  2020cites this paper
• Authors and Contributions

  2019cites this paper
• Bronchoprotective tolerance with inhaled corticosteroid/long-acting β-agonist treatment.

  2019cites this paper
• Genomics and Pharmacogenomics of Severe Childhood Asthma

  2019cites this paper
• ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis

  2018cites this paper
• Chapter 9 – Pharmacogenomics and Applications to Asthma Management

  2018cites this paper
• Can Certain Genotypes Predispose to Poor Asthma Control in Children? A Pharmacogenetic Study of 9 Candiate Genes in Children with Difficult Asthma Certain Genotypes Predispose to Genes

  2018cites this paper
• Design of Clinical Trials and Studies

  2018cites this paper
• Asthma Step-Down Strategies: Perhaps the Patient Should Decide?

  2018cites this paper
• University of Dundee Pharmacogenetics of inhaled long-acting beta2-agonists in asthma

  2018cites this paper
• ADRB 2 Arg 16 Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment : A Systematic Review and Meta-Analysis

  2018cites this paper
• Erratum to “ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis”

  2018cites this paper
• Pharmacogenetics of inhaled long‐acting beta2‐agonists in asthma: A systematic review

  2018cites this paper
• Debate on long-acting β agonists for asthma: they think it's all over.

  2017cites this paper
• Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary disease.

  2017cites this paper
• Concerns with beta2-agonists in pediatric asthma - a clinical perspective.

  2017cites this paper
• Compartmentalized signaling in the lung

  2016cites this paper
• Is Gly16Arg β2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?

  2016cites this paper
• Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment.

  2016cites this paper
• ADRB2 and ACE Gene Polymorphisms in COPD Susceptibility

  2016cites this paper
• 45 – Genetics in Asthma and COPD

  2016cites this paper
• Effects of the inverse alpha‐agonist doxazosin in allergic rhinitis

  2016cites this paper
• Childhood asthma exacerbations and the Arg 16 2-receptor polymorphism

  2015cites this paper
• β2-Adrenergic receptor Gly16Arg polymorphism and impaired asthma control in corticosteroid-treated asthmatic adults.

  2015cites this paper
• Pharmacogenomics of long-acting β2-agonists

  2015cites this paper
• Asthma pharmacogenetics and the development of genetic profiles for personalized medicine

  2015cites this paper
• Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis

  2015cites this paper
• Indirect bronchial provocation tests in childhood asthma

  2015cites this paper
• Genetics of Asthma

  2015cites this paper
• Do genetic polymorphisms alter patient response to inhaled bronchodilators?

  2014cites this paper
• Emerging role of long acting muscarinic antagonists for asthma

  2014cites this paper
• Influence of β2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in patients with persistent asthma.

  2014cites this paper
• Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management

  2014cites this paper
• Current and novel bronchodilators in respiratory disease

  2014cites this paper
• Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine.

  2014cites this paper
• Reply: Pharmacological obfuscation of clinical relevance.

  2014cites this paper
• The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma

  2014cites this paper
• Pharmacogenetics : the science of predictive clinical pharmacology

  2014cites this paper
• Influence of β(2)-adrenergic receptor polymorphism on methacholine hyperresponsiveness in asthmatic patients.

  2013cites this paper
• Can Certain Genotypes Predispose to Poor Asthma Control in Children? A Pharmacogenetic Study of 9 Candidate Genes in Children with Difficult Asthma

  2013influential citation
• Reply: Adverse effects of long-acting beta-agonists on airway hyperresponsiveness.

  2013cites this paper
• Adverse effects of long-acting beta-agonists on airway hyperresponsiveness.

  2013cites this paper
• Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.

  2013cites this paper
• Pharmacogenetics and the Development of Personalized Approaches for Combination Therapy in Asthma

  2013cites this paper
• The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients.

  2013cites this paper
• Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.

  2013cites this paper
• Are inhaled longacting β2 agonists detrimental to asthma?

  2013cites this paper
• Asthma pharmacogenetics: responding to the call for a personalized approach

  2013cites this paper
• β-Adrenoceptor genotype and bronchoprotective subsensitivity with long-acting β-agonists in asthma.

  2013cites this paper
• Tailored second-line therapy in asthmatic children with the Arg(16) genotype.

  2013cites this paper
• Pharmacogenetics of asthma controller treatment

  2012cites this paper
• Pharmacogenetics of Asthma

  2012cites this paper
• Design of Clinical Studies and Trials

  2012cites this paper
• Effects of the β‐agonist, isoprenaline, on the down‐regulation, functional responsiveness and trafficking of β2‐adrenergic receptors with N‐terminal polymorphisms

  2012influential citation
• Pharmacogenomic Testing in the Asthma Clinic: Will Inhaled Corticosteroids Lead the Way?

  2012cites this paper
• 9. Pharmacogenetics of Asthma and COPD

  2012cites this paper
• Long‐ And Ultra‐Long‐Acting β22‐Agonists

  2012cites this paper
• Pharmacogenetics of β2 adrenergic receptor gene polymorphisms, long‐acting β‐agonists and asthma

  2011cites this paper
• Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy

  2011cites this paper
• β-agonist safety and the elephant in the room?

  2010cites this paper
• Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism

  2010cites this paper
• Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.

  2010cites this paper
• Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD.

  2010cites this paper
• Vitamin D and COPD: seasonal variation is important

  2010cites this paper
• The role of pharmacogenomics in improving the management of asthma.

  2010cites this paper
• Role ofADRB2 gene polymorphism in asthma and response to β2-agonists in Polish children

  2010cites this paper
• Pharmacogenetics of asthma

  2009cites this paper
• Chapter 4 – Genetics of Asthma and COPD

  2009cites this paper
• Childhood obstructive sleep apnea contributes to a leading health burden.

  2009cites this paper
• Think the impossible: beta-blockers for treating asthma.

  2009cites this paper
• Omalizumab and Other New Drug Therapies Occupy a Small Space in Asthma Disease Management

  2009cites this paper
• Role of ADRB2 gene polymorphism in asthma and response to beta(2)-agonists in Polish children.

  2009cites this paper
• Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations.

  2009cites this paper
• Recent advances in pediatric asthma treatment

  2009cites this paper
• Genetic and Molecular Regulation of β 2 -Adrenergic Receptors

  2009cites this paper
• Long-Acting β2 Agonists and Inhaled Corticosteroids in Asthma

  2009cites this paper
• Safety aspect of β2-agonists in chronic obstructive pulmonary diesease

  2009cites this paper
• In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes.

  2009cites this paper
• Effect of β2-Adrenergic Receptor Polymorphism in Asthma Control of Patients Receiving Combination Treatment

  2009cites this paper
• Long-acting beta2 agonists and inhaled corticosteroids in asthma.

  2009cites this paper
• Risk-Benefit of Asthma Therapy in Children: Topical Corticosteroids

  2009cites this paper
• Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.

  2009cites this paper
• Clinical consequences of ADRbeta2 polymorphisms.

  2008cites this paper
• Formoterol fumarate inhalation solution (Perforomist™) for COPD

  2008cites this paper
• Pediatric asthma and related allergic and nonallergic diseases: patient-oriented evidence-based essentials that matter

  2008cites this paper
• Pharmacogenomics of Asthma: Do We Know Anything Yet?

  2008cites this paper
• Genetic influences on response to asthma pharmacotherapy

  2008cites this paper
• Pharmacogenetic response to albuterol among asthmatics.

  2008cites this paper
• A simple and rapid genotyping assay for simultaneous detection of two ADRB2 allelic variants using fluorescence resonance energy transfer probes and melting curve analysis.

  2008cites this paper
• Prenatal β 2 -Adrenergic Receptor Signaling and Autism:

  2008cites this paper
• Long-acting β2-adrenoceptor agonists: a smart choice for asthma?

  2007cites this paper
• Many asthma patients experience persistent symptoms despite appropriate clinical and guideline‐based treatment with inhaled corticosteroids

  2007cites this paper
• Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines.

  2007cites this paper
• Genetic profiling and tailored therapy in asthma: are we there yet?

  2007cites this paper
• Long-acting beta2-adrenoceptor agonists: a smart choice for asthma?

  2007cites this paper
• Tolerability Profiles of Leukotriene Receptor Antagonists and Long-Acting β2-Adrenoceptor Agonists in Combination with Inhaled Corticosteroids for Treatment of Asthma: A Review

  2007cites this paper